Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/CD20/CD22 CAR-T cells + X in relapsed/refractory B-cell malignancies
ChiCTR2100049709Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Aug 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LCAR-AIO in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) and 6 more, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: overall response rate. Started Aug 2021; status: recruiting.
02
Drugs
LCAR-AIO
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2100049709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049709.